Surgical therapy for metastatic disease to the liver

被引:91
作者
Bentrem, DJ [1 ]
DeMatteo, RP [1 ]
Blumgart, LH [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Hepatobiliary Serv, New York, NY 10021 USA
来源
ANNUAL REVIEW OF MEDICINE | 2005年 / 56卷
关键词
colorectal metastases; colorectal cancer; hepatic resection; metastasis; chemotherapy;
D O I
10.1146/annurev.med.56.082103.104630
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The liver is a common site of hematogenous metastasis. In the past, patients with liver metastases were often deemed inoperable, and medical therapy conferred only minor survival benefit. However, advances in surgical techniques and chemotherapeutic agents during the past two decades have led to effective treatments for selected patients with metastases to the liver. Up to similar to80% of the liver can be resected, and partial hepatectomy is now routinely performed with a perioperative mortality rate of <5%. Surgical resection of colorectal cancer metastatic to the liver results in a 5-year survival rate of 40%. These results are expected to improve even further with multimodality approaches that include newer chemotherapy regimens. Liver metastases from other primary tumors, such as neuroendocrine carcinoma and genitourinary tumors, are also treated effectively with liver resection. The indications for surgical treatment of liver metastases are broadening as a variety of novel therapies are being developed, including hepatic artery embolization, hepatic artery infusion of chemotherapy, and radiofrequency ablation.
引用
收藏
页码:139 / 156
页数:18
相关论文
共 114 条
[1]  
Adam R, 2001, ANN SURG ONCOL, V8, P347
[2]   Repeat hepatectomy for colorectal liver metastases [J].
Adam, R ;
Bismuth, H ;
Castaing, D ;
Waechter, F ;
Navarro, F ;
Abascal, A ;
Majno, P ;
Engerran, L .
ANNALS OF SURGERY, 1997, 225 (01) :51-60
[3]  
Adam Rene, 2003, Surg Oncol Clin N Am, V12, P211, DOI 10.1016/S1055-3207(02)00085-6
[4]  
ADSON MA, 1984, ARCH SURG-CHICAGO, V119, P647
[5]   Benefits and limits of hepatic resection for gastric metastases [J].
Ambiru, S ;
Miyazaki, M ;
Ito, H ;
Nakagawa, K ;
Shimizu, H ;
Yoshidome, H ;
Shimizu, Y ;
Nakajima, N .
AMERICAN JOURNAL OF SURGERY, 2001, 181 (03) :279-283
[6]   CLINICAL-VALUE OF WHOLE-BODY POSITRON EMISSION TOMOGRAPHY WITH [F-18] FLUORODEOXYGLUCOSE IN RECURRENT COLORECTAL-CANCER [J].
BEETS, G ;
PENNINCKX, F ;
SCHIEPERS, C ;
FILEZ, L ;
MORTELMANS, L ;
KERREMANS, R ;
AERTS, R ;
DEROO, M .
BRITISH JOURNAL OF SURGERY, 1994, 81 (11) :1666-1670
[7]  
BENGMARK S, 1969, CANCER, V23, P198, DOI 10.1002/1097-0142(196901)23:1<198::AID-CNCR2820230126>3.0.CO
[8]  
2-J
[9]   NATURAL-HISTORY OF PATIENTS WITH UNTREATED LIVER METASTASES FROM COLORECTAL-CANCER [J].
BENGTSSON, G ;
CARLSSON, G ;
HAFSTROM, L ;
JONSSON, P .
AMERICAN JOURNAL OF SURGERY, 1981, 141 (05) :586-589
[10]   Cryosurgical ablation and radiofrequency ablation for unresectable hepatic malignant neoplasms -: A proposed algorithm [J].
Bilchik, AJ ;
Wood, TF ;
Allegra, D ;
Tsioulias, GJ ;
Chung, M ;
Rose, DM ;
Ramming, KP ;
Morton, DL .
ARCHIVES OF SURGERY, 2000, 135 (06) :657-662